Share General Information
Acalabrutinib is an oral inhibitor of Bruton’s tyrosine kinase. Acalabrutinib is used in treatment of mantle cell lymphoma (MCL; a fast-growing cancer that begins in the cells of the immune system) who have already been treated with at least one other chemotherapy medication. It is also used to treat chronic lymphocytic leukemia (CLL; a type of cancer in which the bone marrow makes too many lymphocytes) and small lymphocytic lymphoma (SLL: where cancer cells are found mostly in the lymph nodes).
About the API
-
Japan DMF
-
Korea DMF
-
US DMF
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.
